Antares nets $47m from first offering since move to Nasdaq
This article was originally published in Scrip
Executive Summary
Antares Pharma will earn $47 million in net proceeds to fund development of its Vibex disposable pressure-assisted auto injectors for rheumatoid arthritis and male testosterone deficiency drugs through an underwritten offering of 12.5 million shares of common stock closing on 9 October at $4 per share.